» Articles » PMID: 28054827

Amyotrophic Lateral Sclerosis - Frontotemporal Spectrum Disorder (ALS-FTSD): Revised Diagnostic Criteria

Abstract

This article presents the revised consensus criteria for the diagnosis of frontotemporal dysfunction in amyotrophic lateral sclerosis (ALS) based on an international research workshop on frontotemporal dementia (FTD) and ALS held in London, Canada in June 2015. Since the publication of the Strong criteria, there have been considerable advances in the understanding of the neuropsychological profile of patients with ALS. Not only is the breadth and depth of neuropsychological findings broader than previously recognised - - including deficits in social cognition and language - but mixed deficits may also occur. Evidence now shows that the neuropsychological deficits in ALS are extremely heterogeneous, affecting over 50% of persons with ALS. When present, these deficits significantly and adversely impact patient survival. It is the recognition of this clinical heterogeneity in association with neuroimaging, genetic and neuropathological advances that has led to the current re-conceptualisation that neuropsychological deficits in ALS fall along a spectrum. These revised consensus criteria expand upon those of 2009 and embrace the concept of the frontotemporal spectrum disorder of ALS (ALS-FTSD).

Citing Articles

Cognitive impairment within and beyond the FTD spectrum in ALS: development of a complementary cognitive screen.

Michielsen A, van Veenhuijzen K, Hiemstra F, Jansen I, Kalkhoven B, Veldink J J Neurol. 2025; 272(4):268.

PMID: 40074931 PMC: 11903523. DOI: 10.1007/s00415-025-13006-2.


Non-Pharmacological Interventions for Caregivers of People with Motor Neurone Disease: A Scoping Review of Psychosocial Outcomes.

Okoh C, Mayall L, Makin S, Chen C, Zarotti N Brain Sci. 2025; 15(2).

PMID: 40002444 PMC: 11853713. DOI: 10.3390/brainsci15020112.


The Neurodegenerative Disease Knowledge Portal: Propelling Discovery Through the Sharing of Neurodegenerative Disease Genomic Resources.

Dilliott A, Costanzo M, Bandres-Ciga S, Blauwendraat C, Casey B, Hoang Q Neurol Genet. 2025; 11(2):e200246.

PMID: 39996130 PMC: 11849525. DOI: 10.1212/NXG.0000000000200246.


Nemo-like kinase disrupts nuclear import and drives TDP43 mislocalization in ALS.

Bekier 2nd M, Bekier M, Pinarbasi E, Mesojedec J, Ghaffari L, de Majo M bioRxiv. 2025; .

PMID: 39975323 PMC: 11838369. DOI: 10.1101/2025.01.27.635090.


Cognitive and behavioral follow-up of patients with amyotrophic lateral sclerosis type 8.

de Alcantara C, Cruzeiro M, Franca Jr M, Alencar M, de Araujo C, Camargos S Neurol Sci. 2025; .

PMID: 39969750 DOI: 10.1007/s10072-025-08036-7.


References
1.
Branco L, Zanao T, de Rezende T, Casseb R, Balthazar M, Woolley S . Transcultural validation of the ALS-CBS Cognitive Section for the Brazilian population. Amyotroph Lateral Scler Frontotemporal Degener. 2016; 18(1-2):60-67. DOI: 10.1080/21678421.2016.1211147. View

2.
Woolley S, York M, Moore D, Strutt A, Murphy J, Schulz P . Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). Amyotroph Lateral Scler. 2010; 11(3):303-11. DOI: 10.3109/17482961003727954. View

3.
Abrahams S, Newton J, Niven E, Foley J, Bak T . Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 15(1-2):9-14. DOI: 10.3109/21678421.2013.805784. View

4.
Wicks P, Abrahams S, Papps B, Al-Chalabi A, Shaw C, Leigh P . SOD1 and cognitive dysfunction in familial amyotrophic lateral sclerosis. J Neurol. 2009; 256(2):234-41. DOI: 10.1007/s00415-009-0078-0. View

5.
Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand B, de Haan R . The cognitive profile of ALS: a systematic review and meta-analysis update. J Neurol Neurosurg Psychiatry. 2015; 87(6):611-9. DOI: 10.1136/jnnp-2015-310734. View